Samplix is a life science company comprised of an interdisciplinary, dynamic team who shares the vision of better healthcare by providing genomics tools that help determine the genetic architecture of most human diseases and traits. Future healthcare will increasingly depend on accurate detection of genetic variations by genomic analyses. Samplix’ proprietary droplet technologies have proven to accurately validate gene therapy, identify unintended CRISPR edits, decipher complex genomics structures important for the development of many diseases such as neurological disorders like ALS, Alzheimer’s disease etc. Samplix business aspiration is to become the leading provider of solutions for PCR-free target enrichment and amplification of single molecules for high fidelity molecular biology research.